JP2024504225A - Ｓａｒｓ－ｃｏｖ－２抗ウイルス薬としてのリポペプチド融合阻害物質 - Google Patents

Ｓａｒｓ－ｃｏｖ－２抗ウイルス薬としてのリポペプチド融合阻害物質 Download PDF

Info

Publication number
JP2024504225A
JP2024504225A JP2023523609A JP2023523609A JP2024504225A JP 2024504225 A JP2024504225 A JP 2024504225A JP 2023523609 A JP2023523609 A JP 2023523609A JP 2023523609 A JP2023523609 A JP 2023523609A JP 2024504225 A JP2024504225 A JP 2024504225A
Authority
JP
Japan
Prior art keywords
sars
cov
peptide
lipid
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023523609A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022081711A5 (https=
JP2024504225A5 (https=
Inventor
マッテオ ポーロット，
アン モスコーナー，
スワート， リック デ
ヴリーズ， ローリー デ
ブランカ ホーバット，
シリル マスユー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Erasmus University Medical Center
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Erasmus University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Erasmus University Medical Center filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2024504225A publication Critical patent/JP2024504225A/ja
Publication of JPWO2022081711A5 publication Critical patent/JPWO2022081711A5/ja
Publication of JP2024504225A5 publication Critical patent/JP2024504225A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2023523609A 2020-10-14 2021-10-13 Ｓａｒｓ－ｃｏｖ－２抗ウイルス薬としてのリポペプチド融合阻害物質 Pending JP2024504225A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063091915P 2020-10-14 2020-10-14
US63/091,915 2020-10-14
US202063107429P 2020-10-29 2020-10-29
US63/107,429 2020-10-29
US202163139302P 2021-01-19 2021-01-19
US202163139306P 2021-01-19 2021-01-19
US63/139,302 2021-01-19
US63/139,306 2021-01-19
US202163144606P 2021-02-02 2021-02-02
US63/144,606 2021-02-02
US202163145453P 2021-02-03 2021-02-03
US63/145,453 2021-02-03
PCT/US2021/054789 WO2022081711A1 (en) 2020-10-14 2021-10-13 Lipopeptide fusion inhibitors as sars-cov-2 antivirals

Publications (3)

Publication Number Publication Date
JP2024504225A true JP2024504225A (ja) 2024-01-31
JPWO2022081711A5 JPWO2022081711A5 (https=) 2024-10-18
JP2024504225A5 JP2024504225A5 (https=) 2024-10-18

Family

ID=81208578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023523609A Pending JP2024504225A (ja) 2020-10-14 2021-10-13 Ｓａｒｓ－ｃｏｖ－２抗ウイルス薬としてのリポペプチド融合阻害物質

Country Status (8)

Country Link
US (1) US20240226304A1 (https=)
EP (1) EP4228673A4 (https=)
JP (1) JP2024504225A (https=)
KR (1) KR20240038643A (https=)
CA (1) CA3195563A1 (https=)
IL (1) IL302066A (https=)
TW (1) TW202229316A (https=)
WO (1) WO2022081711A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539225A (ja) * 2021-10-22 2024-10-28 ウィスコンシン アラムニ リサーチ ファンデーション Ｓａｒｓ－ｃｏｖ－２、ｃｏｖｄ－１９疾患を引き起こすウイルスによる感染を抑制するペプチド

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159372A1 (en) * 2021-01-22 2022-07-28 Decoy Therapeutics, Inc. Methods and compositions for treating infections
WO2024016011A2 (en) * 2022-07-15 2024-01-18 The Trustees Of Columbia University In The City Of New York Broad spectrum inhibition of human coronaviruses by lipopeptides derived from the c-terminal heptad repeat of betacoronaviruses
CN115746148B (zh) * 2022-10-14 2023-09-12 中国医学科学院病原生物学研究所 具有冠状病毒rbd和膜融合抑制多肽的蛋白质及其作为冠状病毒抑制剂的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170216448A1 (en) * 2014-05-07 2017-08-03 Cornell University Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them
CN111560054A (zh) * 2020-06-16 2020-08-21 哈尔滨吉象隆生物技术有限公司 抑制新型冠状病毒感染的多肽及其筛选方法
CN111732637A (zh) * 2020-05-25 2020-10-02 上海交通大学 抑制新型冠状病毒SARS-CoV-2感染宿主细胞的多肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5788178B2 (ja) * 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
CA3094136A1 (en) * 2018-01-31 2019-08-08 Verra Therapeutics LLC Methods and compositions for inhibiting adam9 biological activities

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170216448A1 (en) * 2014-05-07 2017-08-03 Cornell University Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them
CN111732637A (zh) * 2020-05-25 2020-10-02 上海交通大学 抑制新型冠状病毒SARS-CoV-2感染宿主细胞的多肽及其应用
CN111560054A (zh) * 2020-06-16 2020-08-21 哈尔滨吉象隆生物技术有限公司 抑制新型冠状病毒感染的多肽及其筛选方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIA, SHUAI ET AL.: ""Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus", CELL RESEARCH, vol. 30, no. 4, JPN6025012279, 30 March 2020 (2020-03-30), pages 343 - 355, ISSN: 0005758780 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539225A (ja) * 2021-10-22 2024-10-28 ウィスコンシン アラムニ リサーチ ファンデーション Ｓａｒｓ－ｃｏｖ－２、ｃｏｖｄ－１９疾患を引き起こすウイルスによる感染を抑制するペプチド

Also Published As

Publication number Publication date
IL302066A (en) 2023-06-01
WO2022081711A1 (en) 2022-04-21
CA3195563A1 (en) 2022-04-21
TW202229316A (zh) 2022-08-01
US20240226304A1 (en) 2024-07-11
EP4228673A4 (en) 2024-11-20
WO2022081711A4 (en) 2022-06-30
EP4228673A1 (en) 2023-08-23
KR20240038643A (ko) 2024-03-25

Similar Documents

Publication Publication Date Title
Yang Application of nanotechnology in the COVID-19 pandemic
JP2024504225A (ja) Ｓａｒｓ－ｃｏｖ－２抗ウイルス薬としてのリポペプチド融合阻害物質
Hoffmann et al. Priming time: how cellular proteases arm coronavirus spike proteins
CN113563433B (zh) 多肽、其制备方法和用途
Zhou et al. Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines
Yu et al. Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
Wu et al. A pan-coronavirus peptide inhibitor prevents SARS-CoV-2 infection in mice by intranasal delivery
Cao et al. Broad-spectrum anti-coronavirus vaccines and therapeutics to combat the current COVID-19 pandemic and future coronavirus disease outbreaks
US12460193B2 (en) Compositions for preventing or treating coronavirus infections
Bovier et al. Inhibition of measles viral fusion is enhanced by targeting multiple domains of the fusion protein
US20240252617A1 (en) Coronavirus spike protein designs, compositions and methods for their use
Ma et al. SARS‐CoV‐2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice
Qiao et al. The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition
KR20230028719A (ko) Sars-cov-2 항바이러스제로서의 지질-펩티드 융합 억제제
US20230270843A1 (en) Post-Exposure Vaccination Against Viral Respiratory Infections
Bi et al. An enhanced broad-spectrum peptide inhibits Omicron variants in vivo
Piepenbrink et al. Potent universal-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody
Krut’ et al. Will peptides help to stop COVID-19?
Noorabad Ghahroodi et al. Recombinant subunits of SARS‐CoV‐2 spike protein as vaccine candidates to elicit neutralizing antibodies
Zandi et al. The Spike Protein Mutations and its Effect on SARS-CoV-2 Pathogenesis
CN117915936A (zh) 作为sars-cov-2抗病毒物的脂质肽融合抑制剂
Lan et al. Coronavirus entry inhibitors
Kadam et al. Molecular and structural insights into COVID-19 pandemic
US20250257099A1 (en) Broad spectrum inhibition of human coronaviruses by lipopeptides derived from the c-terminal heptad repeat of betacoronaviruses
Lainšcek et al. A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response. Vaccines 2021, 9, 431

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251222